Computational Approaches Integrated in a Digital Ecosystem Platform for a Rare Disease

Area of Science:

• Genetics and Bioinformatics
• Rare Diseases Research
• Computational Biology

Background:

• Alkaptonuria (AKU) is an ultra-rare autosomal recessive disorder stemming from homogentisate 1,2-dioxygenase gene mutations.
• A significant challenge in AKU research is the absence of standardized methods for assessing disease severity and treatment efficacy.
• This necessitates innovative approaches for data management and analysis in ultra-rare diseases.

Purpose of the Study:

• To introduce ApreciseKUre, a comprehensive digital platform designed for AKU patient data collection, integration, and analysis.
• To explore the application of machine learning (ML) for analyzing AKU data to facilitate patient stratification and personalized treatment strategies.
• To support the development of a Precision Medicine Ecosystem for AKU by enabling data sharing among researchers and clinicians.

Main Methods:

• Development of the ApreciseKUre multi-purpose digital platform, incorporating genetic, biochemical, histopathological, clinical, and Quality of Life (QoL) data.
• Implementation of machine learning algorithms to analyze the integrated dataset within ApreciseKUre.
• Utilizing computational modeling and database construction for comprehensive patient profiling and biomarker identification.

Main Results:

• The ApreciseKUre platform successfully integrates diverse data types crucial for AKU research.
• Machine learning analysis of ApreciseKUre data demonstrated significant potential for patient stratification.
• Computational modeling and database construction are key to identifying novel biomarkers for personalized AKU therapy.

Conclusions:

• ApreciseKUre serves as a foundational tool for advancing AKU research and fostering a Precision Medicine Ecosystem.
• Machine learning applications on integrated data can lead to tailored therapeutic strategies for AKU patient subgroups.
• The platform and analytical methods pave the way for personalized medicine approaches in AKU, optimizing the benefit-risk ratio.